GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Overview


Chris Bruno will speak on a panel for LSPN Connect on the topic of “GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?” Discussion will include an overview of the role of skinny labelling in the US FDA’s regulation of drug products and the implications of the recent GSK v Teva ruling on patent strategies for brand and generic drug manufacturers.

Click here for more information and to register.

Dig Deeper

Chicago, Illinois / Speaking Engagements / September 1, 2021

2021 ACC Chicago Summit

Webinar / Speaking Engagements / June 24, 2021

Best Practices for Patent Quality

Webinar / Speaking Engagements / May 27, 2021

GSK v Teva: Is the Future of Skinny Labelling to be Reconsidered?

Webinar / Speaking Engagements / May 25, 2021

Intellectual Property and Cannabis

Get In Touch